Company News

MyoStrain® Provides Quantitative Heart Failure Risk Assessment to Help Clinicians Individualize and Monitor Treatment in Asymptomatic Patients with Non-Ischemic Cardiomyopathy

  • The article demonstrates MyoStrain’s clinical utility as a cardiac management tool enabling clinicians to identify asymptomatic cardiac patients for early intervention and individualized treatment
  • MyoStrain provided a sensitive and comprehensive cardiac risk assessment to support the diagnostic classification of patient heart health
  • MyoStrain was able to quantify the extent and severity of dysfunction over traditional metrics such as ejection faction
April 20, 2021
Company News

MORRISVILLE, N.C., April 20, 2021 – A new article published in the Journal of Cardiovascular Magnetic Resonance utilized MyoStrain (fast-SENC) to accurately risk-stratify asymptomatic cardiac patients across multiple disease states. The article demonstrated MyoStrain’s clinical utility as a critical risk stratification tool to help clinicians improve treatment decisions and optimize care.[1]

The study compared MyoStrain’s ability to quantify and differentiate patients based on their cardiac risk versus traditional ejection faction. Observers examined patients present with chronic non-ischemic heart failure caused by dilated cardiomyopathy, hypertrophic cardiomyopathy or cardiac amyloidosis.[1]

MyoStrain enabled clinicians to accurately describe the impact of the disease on patient heart function and plot each patient subject along MyoStrain’s progressive dysfunction curve, a risk stratification tool that allows clinicians to individually classify patients in terms of the ACC/AHA guidelines for heart failure stages. [1],[2]

Professor Henning Steen, MD, Head of Cardiac MRI at Marien Hospital in Hamburg, Germany, and lead author of the article, stated: “MyoStrain offers the visibility needed to help clinicians assess early asymptomatic dysfunction in our patients. It uses a unique and highly sensitive technique to acquire segmental strain, which provides us both the ability to detect and subsequently categorize these patients into risk groups based on the individual patterns and severity of their dysfunction.”

Professor Grigorios Korosoglou, MD, Chief of Cardiology & Vascular Medicine at GRN Hospital and the principal investigator of the study, added: “This study has shown that MyoStrain provides a critical cardiac risk assessment and management tool for patients at risk of heart failure. Through its progressive curve, MyoStrain helps clinicians to not only determine a patient’s risk of developing heart failure, but to individualize care as well by monitoring the effectiveness of treatment on the patient overtime. This may allow clinicians to focus on preventing the progression of heart dysfunction early on for improved clinical outcomes and quality of life for patients.”

Full access to the publication is available here.

[1] Steen, H., et al. J Cardiovasc Magn Reson 23, 45(2021). https://doi.org/10.1186/s12968-021-00711-w

[2] Korosoglou, G et al. J Am Coll Cardiol Cardiovasc Imaging. Jan 13, 2021.DOI: 10.1016/j.jcmg.2020.10.024


Media Contact

Ahmed Osman
PR@myocardialsolutions.com
919.459.9113 

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.